Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?

To: E_K_S who wrote (68522)	9/1/2021 11:53:25 AM
From: Ditchdigger	Respond to of 78777

Thanks, just spotted it. If my position wasn't oversized already, I'd add.

To: E_K_S who wrote (68522)	9/2/2021 11:00:35 AM
From: diegosan	2 Recommendations Recommended By E_K_S Spekulatius Respond to of 78777

The FDA is concerned about JAK inhibitors in inflammatory diseases, brought about by long term studies of PFE's Xeljanz. Not specifically ABBV, but as Humira is nearing patent expiration, their new drug in the JAK inhibitor class, Rinvoq, might not now to be able to fill the revenue gap. Kudos to DewDiligence: investorshub.advfn.com

To: E_K_S who wrote (68522)	10/8/2021 1:38:46 PM
From: Fantik24	Respond to of 78777

Hello. I have no opinion about this company. I have not heard of it before.

To: E_K_S who wrote (68522)	10/11/2021 6:54:17 AM
From: Fantik24	Read Replies (2) \| Respond to of 78777

Hello. I have no opinion about this company. I have not heard of it before. If their residential home products are that good, I would love to buy a home built using their products, if that is true, of course. I recently started investing, hoping that my income would increase several times over and buy a house, but my expectations were too high. That's because the investment was relatively paltry. My friend Jal suggested taking out a mortgage loan; he talked to me for a long time, telling me all the pros and cons. Finally, I agreed to meet with a Mortgage Advisor, Sheffield. And he proved to me that it was a good idea. Soon I would have my own house, yay!

To: E_K_S who wrote (68522)	10/21/2021 7:21:10 PM
From: Rarebird	Read Replies (3) \| Respond to of 78777

ABBV is a $145 stock based on my technical indicators. There was a lot of damage done to the chart, but nothing that can't be repaired over the next 12 months. Fundamentally, the news concerning the heart problems associated with the drug was an orchestrated endeavor to push the stock lower and it was successful. It is amazing sometimes to see what the Street will hype to achieve its goals. Took a long position in ABBV today. $105.50 is strong support. Below $102 head for the hills. For me, it is all about Risk vs Reward. The patient, ABBV, is recovering nicely. I have a very healthy prognosis, a Hallmark movie ending for the stock over the next 12 months. Sometimes the light does emerge from the Dark .